Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline and emerging drugs for the treatment of peripheral neuropathy and neuropathic pain
| Price: £1,499.00 Approx $2,236.81 (USD) €1,676.26 (EUR) |
|
|---|---|
| Overview: | |
| This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a comprehensive update on all current drugs, together with the entire drug development pipeline, from pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates being developed to treat PN and NP as a primary indication and 60 "second-indication" drugs. More than 300 patents published in the PN and NP field between 2002 and 2008 have also been assessed and presented, together with the identification of potential candidate molecules and drug targets which have not entered the development pipeline, but which may do so in the future. This report was written to provide a comprehensive update on therapeutic developments relating to PN and NP, both in tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the underlying disease mechanisms. Commercial evaluation and assessments including markets, market size, market sectors, sales and trends relating to PN and NP are also included in this report. | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr John Bates / Publication Date: 1st January 2008
Contents:
1. Background
This introductory chapter gives a general overview of peripheral neuropathy (PN) and neuropathic pain (NP) including classification, causes, treatments and unmet need.
1.1 Peripheral Neuropathy
1.1.1 Classification
1.1.2 Causes
1.1.3 Treatments
1.1.4 Unmet Need
1.1.5 Discussion
1.2 Neuropathic Pain
1.2.1 Classification
1.2.2 Causes
1.2.3 Treatments
1.2.4 Unmet Need
1.2.5 Discussion
2. Prevalence and Trends
PN and NP are causally linked to a number of conditions, several of which are major global diseases such as diabetes, cancer and HIV infection. Chapter 2 gives an overview of the prevalences of PN and NP covering the major disease associations including diabetes, autoimmune disease, viral infections, gastrointestinal conditions, cancer, drug and toxin, autonomic nervous system, nerve compression and hereditary related. The prevalences of PN and NP are assessed for each of these, to allow global levels to be calculated.
2.1 Causal Links
2.1.1 Diabetes
2.1.2 Autoimmune
2.1.3 Infection
2.1.3.1 HIV
2.1.3.2 Herpes Zoster
2.1.4 Gastrointestinal
2.1.5 Drugs and Toxins
2.1.6 Cancer
2.1.7 Autonomic
2.1.8 Heredity
2.1.9 Compression
2.2 Neuropathic Pain
2.3 Trends
3. Therapeutic Pipeline
This chapter gives a detailed presentation of the drug development pipeline, covering approximately 80 drugs being developed to treat PN and NP as primary indications and around 60 candidates, which are second-indication treatments.
3.1 Primary Indication Drugs
3.1.1 Launched/Pre-Registration
3.1.2 Phase III
3.1.3 Phase II
3.1.4 Phase I
3.1.5 Pre-clinical
3.2 Secondary Indication Drugs
3.2.1 Launched/Pre-Registration
3.2.2 Phase III
3.2.3 Phase II
3.2.4 Phase I
3.2.5 Pre-clinical
3.3. Discussion
4. Emerging Technology
This chapter presents and summarises over 300 patent filings relevant to the therapeutic targeting of PN and NP. These were published between Jan 2002 and July 2007. This review was been carried out to identify emerging therapeutic opportunities, which have not yet entered the drug development pipeline.
4.1 Patents
4.2 Drug Targets
4.3 Peripheral Neuropathy
4.4 Neuropathic Pain
4.5 Discussion
4.6 Companies/Assignees
5. Markets
An overview of markets relating to PN and NP including products, sales, market size, trends and companies.
5.1 Products
5.2 Sales
5.3 Market Size
5.4 Trends
5.5 Companies
6. Discussion
Chapter 6 gives a comprehensive overview and discussion on the findings of this report.
6.1 Overview
6.2 Prevalence and Trends
6.3 Unmet Need
6.3.1 Peripheral Neuropathy
3.3.2 Neuropathic Pain
6.3.2 Targeting the Diseases
6.3.4 Reversing the Disease
6.4 Drug Targets
6.5 Current Treatments
6.5.1 Peripheral Neuropathy
6.5.2 Neuropathic Pain
6.6 Drug Pipeline
6.6.1 Peripheral Neuropathy
6.6.2 Neuropathic Pain
6.7 Markets
6.8 Conclusions
List of Tables:
List of Tables
Table 1. Drugs and chemical toxins known to cause peripheral neuropathy
Table 2. Global prevalence of peripheral neuropathy
Table 3. Drugs and developmental candidates (pre-clinical to launch) for the treatment of PN and NP, as primary indications
Figure 4. Drugs and developmental candidates (pre-clinical to launch) for the treatment of PN and NP, as secondary indications
Table 5. Drugs for the treatment of peripheral neuropathy and neuropathic pain
Table 6. Sales of drugs for the treatment of peripheral neuropathy and neuropathic pain
Table 7. Candidate drug molecules and potential drug targets which are not identified in the drug development pipeline
Table 8. Drug targets of candidates in the pipeline, by development phase (primary indications)
Table 9. Drug targets of candidates in the pipeline, by development phase (secondary indications)
Table 10. Drug targets of candidates in the pipeline, by development phase (primary and secondary indications)
Figure 1. Diabetes: The highest national levels (top 5 countries)
Figure 2. Diabetes: The highest national prevalence (top five countries)
Figure 3. Candidates at each development stage in the drug pipeline for the treatment of PN and NP, as primary indications
Figure 4. Primary indication candidates in the drug pipeline for the treatment of PN and NP, by therapeutic group
Figure 5. Secondary indication candidates in the drug pipeline for the treatment of PN and NP, by therapeutic group
Figure 6. Secondary indication candidates in the drug pipeline for the treatment of PN and NP, by primary indication therapeutic group
Figure 7. Candidates at each development stage in the drug pipeline for the treatment of PN and NP, as secondary indications
Figure 8. Market sectors: PN and NP
Figure 9. Number needed to treat (NNT) for different types of neuropathic pain: tricyclic antidepressants (Treat A), serotonin noradrenaline reuptake inhibitors (Treat B), gabapentin/pregabalin (Treat C), opioids (Treat D), tramadol (Treat E), NMDA antagonists (Treat F), topical lidocaine (Treat G), cannabinoids (Treat H) and capsaicin (Treat I).
Appendix 1. Patents relating to drug candidates and potential drug targets for the treatment of PN and NP, published from Jan 2002 to July 200